Minimal Residual Disease in Solid Tumors: Principles and Applications of Circulating Tumor DNA

Circulating tumor DNA (ctDNA) is emerging as a powerful biomarker for detecting minimal residual disease (MRD) in patients with solid tumors. Join the Association for Molecular Pathology for a webinar at 1 pm ET that reviews the principles, technologies, and clinical applications of ctDNA-based MRD detection, focusing on the opportunities and challenges of identifying molecular evidence of residual disease before it becomes clinically apparent.